The Asia-Pacific Non-Insulin Diabetes Therapies market size is estimated to value USD 9.46 billion by 2026 from USD 6.55 billion in 2021, growing at a CAGR of 7.62% during the forecast period.
The change in lifestyle and food habits is the cause of diabetes. Over the recent period, the significant increase in diabetes patients, growing demand for combination therapy, and rapid advancements in diabetes treatment are fuelling the APAC non-insulin therapies for diabetes market growth. In comparison to the Western population, Asians get diabetes at a younger age. The sudden shift in lifestyle brought on by fast economic growth is the cause of this early diabetes incidence. Asia accounts for around 60% of the overall number of diabetic patients worldwide. The most apparent explanation for this is that Asia has two of the world's most populous countries, such as China and India. Therefore, the increase in the number of people with type 2 diabetes and the spread of diabetes among adults aged 6 to 35 is expected to propel the market upward.
Type 2 diabetes is treated using combination treatments, such as injecting anti-hyperglycemic medications alone or in conjunction with insulin. Furthermore, on the demand side, the rising number of persons with type 2 diabetes is the primary cause for the increased adoption of non-insulin treatments across APAC.
APAC has witnessed technological advancements in the healthcare sector due to the growing investments by government and non-government organizations. The major market players in the region are incorporating advanced technologies in their products. Advanced technology is being incorporated into the products of the region's leading market participants. These technologies can anticipate, monitor, and adapt to their environment. These technical advancements give producers a competitive advantage over their competitors, allowing them to maintain a stranglehold on the APAC non-insulin diabetic treatments market.
Additionally, key market players are adopting strategies such as partnerships, collaborations, and mergers, which are expected to impact market growth positively; these strategies allow them to expand their business globally. Also, these techniques allow businesses to reach out to previously untapped markets that may have been beneficial. These methods also assist companies in gaining resources that will help them stay afloat and succeed in the APAC non-insulin diabetic treatments market.
However, many people in rural areas are still unaware of the benefits of these medicines, thus raising awareness is a problem. In addition, diabetes is a prevalent condition, therefore making these medicines available to individuals of all socioeconomic groups is a major challenge. Also, the government initiatives about increasing people’s attention are not in huge numbers and thus restrict the market's growth.
This research report on the APAC Non-insulin diabetes therapies market has been segmented and sub-segmented into the following categories:
By Drug Type:
By Country:
By geography, the APAC is one of the fast-growing regions globally in the Non-Insulin Diabetes Therapies Market. The market held a significant share in the market and is most likely to have a significant share during the forecast period. The market growth in the region is attributed to the proliferation of diabetes, the growing geriatric population, and the rising quality of healthcare services in the region. The APAC regional market growth is expanding due to two highly populated countries such as China and India. China got more people with diabetes than any other country globally, which surpassed India in the recent past. In India, about 62 million people are facing problems related to Diabetics. Because of the growth in the number of people facing diabetic problems, the growth in this market is expected to increase exponentially in the coming years. Over the forecast period, China witnessed the highest share in the market. China has more diabetic patients than any other country globally, surpassing India in the recent past. In addition, China has adopted advanced technology in the healthcare sector, which is majorly boosting the country-side market growth.
On the other hand, the Indian insulin diabetes market is anticipated to showcase a promising share and contribute to the APAC regional market expansion. In India, about 62 million people are facing problems related to Diabetics. About 80 thousand deaths are expected to occur in America because of diabetes, and recent studies show us that around 1.4 million people have been diagnosed and treated for Type-2 Diabetes. The Indian market is propelled by unhealthy lifestyles and initiatives taken by the government for creating awareness among the people about diabetes and the benefits of the drugs.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the APAC non-insulin diabetes therapies market profiled in this report are Tobira (New Jersey), Eli Lilly and Sumitomo Dainippon Pharma (Japan), Novo Nordisk (Denmark), Takeda (Japan), Sanofi (China), Mannkind (California), Bristol-Myers Squibb (New York), AstraZeneca (U.K), Boehringer Ingelheim (Germany) and Bayer (Germany).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 Sulphonylureas
5.1.3 Amylin Agonists
5.1.4 GLP-1 Agonists & Analogs
5.1.5 Biguanides
5.1.6 Glinides & Meglinitides
5.1.7 Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors
5.1.8 Thiazolidinediones (or Glitazones or TZDs
5.1.9 Alpha-Glucosidase Inhibitors
5.1.10 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
5.1.11 Y-o-Y Growth Analysis, By Drug Type
5.1.12 Market Attractiveness Analysis, By Drug Type
5.1.13 Market Share Analysis, By Drug Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Product
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Tobira
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novo Nordisk
8.3 Takeda and Sanofi
8.4 Eli Lilly Sumitomo Dainippon Pharma
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
